Lyra Therapeutics Appoints New CMO, Director

Ticker: LYRA · Form: 8-K · Filed: Apr 19, 2024 · CIK: 1327273

Lyra Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyLyra Therapeutics, INC. (LYRA)
Form Type8-K
Filed DateApr 19, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: management-change, board-appointment

TL;DR

Lyra Therapeutics brings in a new CMO and adds a director to the board.

AI Summary

Lyra Therapeutics, Inc. announced on April 15, 2024, the appointment of Dr. Jeffrey L. Meckler as Chief Medical Officer and the election of Ms. Jennifer M. McNeely to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers, though specific dollar amounts were not detailed in this filing.

Why It Matters

Changes in key leadership roles like Chief Medical Officer and Board of Directors can signal strategic shifts or new directions for a biotechnology company, potentially impacting its research and development pipeline.

Risk Assessment

Risk Level: medium — Changes in executive and board positions can indicate internal shifts that may affect the company's future strategy and performance.

Key Players & Entities

FAQ

Who has been appointed as the new Chief Medical Officer of Lyra Therapeutics?

Dr. Jeffrey L. Meckler has been appointed as the new Chief Medical Officer.

Who has been elected to the Board of Directors of Lyra Therapeutics?

Ms. Jennifer M. McNeely has been elected to the Board of Directors.

What is the exact date of the earliest event reported in this 8-K filing?

The earliest event reported is dated April 15, 2024.

What is the company's state of incorporation?

Lyra Therapeutics, Inc. is incorporated in Delaware.

What is the business address of Lyra Therapeutics?

The business address is 480 Arsenal Way, Watertown, MA 02472.

Filing Stats: 455 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-04-19 16:17:06

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 19, 2024 Lyra Therapeutics, Inc. By: /s/ Jason Cavalier Jason Cavalier Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing